Journal article
Advances in anti-epileptic drug testing
Clinica chimica acta, Vol.436, pp.224-236
09/25/2014
DOI: 10.1016/j.cca.2014.06.002
PMID: 24925169
Abstract
In the past twenty-one years, 17 new antiepileptic drugs have been approved for use in the United States and/or Europe. These drugs are clobazam, ezogabine (retigabine), eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. Therapeutic drug monitoring is often used in the clinical dosing of the newer anti-epileptic drugs. The drugs with the best justifications for drug monitoring are lamotrigine, levetiracetam, oxcarbazepine, stiripentol, and zonisamide. Perampanel, stiripentol and tiagabine are strongly bound to serum proteins and are candidates for monitoring of the free drug fractions. Alternative specimens for therapeutic drug monitoring are saliva and dried blood spots. Therapeutic drug monitoring of the new antiepileptic drugs is discussed here for managing patients with epilepsy.
•We review the practice of therapeutic drug monitoring for newer anti-epileptic drugs.•We present the pharmacokinetic factors influencing dosing of anti-epileptic drugs.•We discuss monitoring using serum/plasma, saliva, and dried blood spots.
Details
- Title: Subtitle
- Advances in anti-epileptic drug testing
- Creators
- Matthew D Krasowski - Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, United StatesGwendolyn A McMillin - Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, United States
- Resource Type
- Journal article
- Publication Details
- Clinica chimica acta, Vol.436, pp.224-236
- Publisher
- Elsevier B.V
- DOI
- 10.1016/j.cca.2014.06.002
- PMID
- 24925169
- ISSN
- 0009-8981
- eISSN
- 1873-3492
- Language
- English
- Date published
- 09/25/2014
- Academic Unit
- Pathology
- Record Identifier
- 9984047691502771
Metrics
20 Record Views